Coronavirus company news summary - Avacta Group begins shipping antigen lateral flow test - Bio-Techne to launch RNAscope technology to detect SARS-CoV-2 in tissues - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Avacta Group begins shipping antigen lateral flow test – Bio-Techne to launch RNAscope technology to detect SARS-CoV-2 in tissues

05 Aug 2021

Avacta Group has begun shipment of its AffiDX SARS-CoV-2 antigen lateral flow test, which uses nasal swabs to deliver results within 20 minutes. The CE marked test is intended for use by professionals in the UK and EU. Avacta selected Calibre Scientific as its first distributor for the test in these regions and is working to collaborate with several other distributors and end-users in Europe, the UK and Asia among other regions.

Bio-Techne, through its brand Advanced Cell Diagnostics, is set to launch RNAscope technology to detect SARS-CoV-2 in fixed tissues. The technology comes with one of the probes that were used as an Analyte Specific Reagent (ASR) in a study specific to the mRNA of Spike protein of the virus. The probe demonstrated efficacy in detecting viral targets in tissues. The ASR is expected to offer a beneficial tool for researchers and pathologists to identify SARS-CoV-2.

Biozek Medical has introduced its Covid-19 Antigen Saliva Rapid test for the detection of all known mutating SARS-CoV-2 variants. The non-invasive test can be administered by a healthcare expert or self-administered, with results obtained within 15 minutes. The test is designed to address “Nasal Swab Fatigue” by offering a saliva-based alternative to nasal and nasopharyngeal swab tests.